Related Experiment Video
Updated: Jun 4, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled
J Hermanides1, K Nørgaard, D Bruttomesso
1Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands. j.hermanides@amc.uva.nl
Diabetic Medicine : a Journal of the British Diabetic Association
|February 8, 2011
Summary
Sensor-augmented insulin pump therapy significantly improved glycemic control in Type 1 diabetes patients. This advanced treatment lowered HbA1c levels effectively without increasing hypoglycemia risk compared to multiple daily injections.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Diabetes Technology
Background:
- Type 1 diabetes management often involves multiple daily injections (MDI).
- Suboptimal glycemic control (HbA1c ≥ 8.2%) necessitates exploring advanced therapeutic options.
- Continuous glucose monitoring integrated with insulin pumps offers potential benefits.
Purpose of the Study:
- To compare the efficacy of sensor-augmented insulin pump (SAP) therapy against MDI in Type 1 diabetes patients with suboptimal glycemic control.
- To assess changes in HbA1c, sensor-derived metrics, and patient-reported outcomes.
Main Methods:
- An investigator-initiated, multi-center trial (Eurythmics Trial) randomized 83 Type 1 diabetes patients (HbA1c ≥ 8.2%) to either SAP therapy (n=44) or MDI (n=39) for 26 weeks.
- Primary endpoint was the change in HbA1c from baseline to 26 weeks.
- Secondary endpoints included sensor-derived glycemic control and patient-reported outcomes.
Main Results:
- SAP therapy significantly reduced HbA1c by -1.21% (P < 0.001) compared to MDI over 26 weeks.
- The SAP group achieved target HbA1c levels (7.23%) without an increase in hypoglycemia.
- Patient-reported outcomes, including diabetes management satisfaction, improved in the SAP group.
Conclusions:
- Sensor-augmented pump therapy is an effective strategy for improving glycemic control in Type 1 diabetes patients previously managed with MDI.
- SAP therapy offers a viable alternative for patients with suboptimally controlled Type 1 diabetes, enhancing both clinical and patient-reported outcomes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...